Leconotide

Leconotide (also known as SNX-111) is a synthetic version of a conotoxin protein, which is derived from the venom of the marine cone snail species Conus magus. It is a potent analgesic compound that has been developed for the treatment of severe chronic pain.

History

Leconotide was first isolated from the venom of Conus magus in the 1980s. The compound was then synthesized and developed as a potential therapeutic agent by the pharmaceutical company Neurex. In 2000, Neurex was acquired by Elan Corporation, which continued the development of leconotide.

Pharmacology

Leconotide is a peptide that acts as a N-type calcium channel blocker. It binds to these channels in the spinal cord and inhibits the release of neurotransmitters that signal pain. This mechanism of action is unique among analgesics and gives leconotide a high degree of efficacy in the treatment of severe chronic pain.

Clinical use

Leconotide is used in the treatment of severe chronic pain that is not responsive to other forms of analgesic therapy. It is administered via intrathecal injection, which delivers the drug directly into the spinal fluid. This method of administration allows for a high degree of efficacy and minimizes systemic side effects.

Side effects

The most common side effects of leconotide include nausea, dizziness, and confusion. These side effects are generally mild and transient. However, leconotide can also cause more serious side effects, such as respiratory depression and hypotension, especially at high doses.

See also

• Conotoxin
• Analgesic
• Neurex
• Elan Corporation